US-based Volcano has initiated the limited market release of its US Food and Drug Administration (FDA) cleared and CE marked SyncVision technology system in the US and Europe.
The on-line image processing workstation allows the physician to navigate simultaneously on an angiogram and to correlate significant IVUS findings with the corresponding spots using co-registration of the Eagle Eye Platinum catheter with x-ray angiography.
SyncVision provides the detailed vessel, lumen and wall structure from angiography and the spatial localization of Volcano’s intravascular ultrasound images within the coronary tree together in a co-registered view to facilitate more informed treatment decisions and more efficient, enhanced workflow performance.
University of Washington Medical Center Director Cardiac Catheterization Laboratory and Clinical Associate Professor of Medicine Dr Steven Goldberg said SyncVision allows us to correlate significant IVUS findings with the corresponding spots on the angiogram.
"This addresses a challenging aspect of current practice in that it can be difficult to identify the precise spot needing treatment in translating the IVUS findings to the angiogram," Dr Goldberg added.
"It also allows for simple and precise length measurements to help inform stent selection. Co-registration of different imaging modalities is currently the wave in interventional cardiology, and I think this is one of the most useful and user friendly co-registration formats I have seen. I believe that this truly represents the next generation in IVUS imaging."
SyncVision is currently installed in multiple limited market release sites throughout US and Europe. The company also anticipates the full market release in later 2014.
The company is planning to share the SyncVision technology with a global audience next month at the EuroPCR meeting in Paris.